comparemela.com
Home
Live Updates
Aditxt, Inc. Enters into Definitive Agreement to Acquire Evofem Biosciences, Inc., Creator of Phexxi®, the First and Only FDA-Approved Hormone-Free Contraceptive Gel, to Address Diverse Reproductive Health Needs of Women Globally : comparemela.com
Aditxt, Inc. Enters into Definitive Agreement to Acquire Evofem Biosciences, Inc., Creator of Phexxi®, the First and Only FDA-Approved Hormone-Free Contraceptive Gel, to Address Diverse Reproductive Health Needs of Women Globally
Evofem posted $13.4 million in net sales of Phexxi for the first nine months of 2023;
Aditxt looks to accelerate Evofem into the global non-hormonal birth control market valued at $27.7 billion in...
Related Keywords
United States
,
Amro Albanna
,
Saundra Pelletier
,
Evofem Biosciences Inc
,
Exchange Commission
,
Aditxt Inc
,
Women Reproductive Health
,
Un Department Of Economic
,
Population Division
,
Securities Exchange
,
United Nations Department Of Economic
,
Evofem Biosciences
,
Reproductive Health
,
Unlocking Evofem
,
Global Potential
,
Growth Plus Reports
,
Accelerating Promising
,
Securities Purchase
,
Security Agreement
,
Chief Executive Officer
,
Current Report
,
Nations Department
,
Social Affairs
,
World Family Planning
,
Non Hormonal Birth Control Market
,
Contraceptive Devices
,
Global Outlook
,
Registration Statement
,
Securities Exchange Act
,
Private Securities Litigation Reform Act
,
Nasdaq Stock Market
,
Annual Report
,
Quarterly Report
,
Markets
,
comparemela.com © 2020. All Rights Reserved.